Melbourne (Australia) | 03 June 2024

Telix today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET1 agent, TLX250-CDx (Zircaix®2, 89Zr-DFO-girentuximab), for the characterisation of renal masses as clear cell renal cell carcinoma (ccRCC). 

The rolling BLA submission, initiated in December 20233 with timelines pre-agreed with the FDA, was based on Telix’s successful global Phase III ZIRCON4 study in ccRCC. The clear cell variant of renal cancer is the most common and aggressive sub-type of kidney cancer. The ZIRCON study met all co-primary and secondary endpoints, demonstrating a sensitivity of 86%, specificity of 87% and a positive predictive value (PPV) of 93% for ccRCC, including in small, difficult to detect lesions5

As part of the BLA submission process, Telix has requested a Priority Review under the eligibility criteria of the Breakthrough Therapy designation6. If granted, this would potentially support an expedited review time. If Zircaix®2 is approved, TLX250-CDx will be the first targeted radiopharmaceutical imaging agent specifically for kidney cancer to be commercially available in the U.S. and further builds on Telix’s successful urology imaging franchise. 

James Stonecypher, Chief Development Officer at Telix, stated, “Completing the BLA submission for TLX250-CDx represents a significant milestone for Telix as we bring our Breakthrough investigational kidney cancer imaging agent closer to market as a non-invasive diagnostic for patients. We believe TLX250-CDx is a natural follow-on product to Illuccix® as it is targeted at the same clinical stakeholders, the urologist and urologic oncologist, and leverages the proven commercial and distribution infrastructure developed through the launch of Illuccix®.” 

TLX250-CDx International Expanded Access 

As part of Telix’s commitment to access to medicine, the Company has opened an expanded access program (EAP) in the U.S.7, named patient programs (NPPs) in Europe, and a special access scheme (SAS) in Australia to allow continued access to TLX250-CDx outside of a clinical trial to patients for whom there are no comparable or satisfactory alternate options. 

U.S. patients, or physicians who may have eligible patients in the U.S., can e-mail or complete the form here for further information. 

Physicians in Europe and Australia who may have eligible patients can email and, respectively, for further information about TLX250-CDx named patient access.  

Telix’s Policy on Offering Compassionate Use to Investigational Medicines can be downloaded at the following link

For more information about ongoing clinical trials of TLX250-CDx, please visit  

Read the full ASX announcement here.

TLX250-CDx has not received a marketing authorisation in any jurisdiction.

  1. Positron emission tomography. ↩︎
  2. Brand name subject to final regulatory approval.  ↩︎
  3. Telix ASX disclosure 19 December 2023. ↩︎
  4. Zirconium in Renal Cancer Oncology, ID: NCT03849118. ↩︎
  5. Telix ASX disclosures 7 November 2022.  ↩︎
  6. Telix ASX disclosure 1 July 2020. ↩︎
  7. ID: NCT06090331↩︎